
医学资讯BYQLOVI丙酸氯倍他索
0.05% 丙酸氯倍他索混悬滴眼液:白内障术后炎症和疼痛管理的新里程碑
By MedXY|2026年5月12日
本综述综合了 BYQLOVI®(0.05% 丙酸氯倍他索)的临床证据,强调其快速疗效、卓越的疼痛缓解效果以及优于传统眼部类固醇的安全性。
Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.